Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Depreciation & Amortization (CF) (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 88.89% to $1000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $20000.0, a 51.22% decrease, with the full-year FY2024 number at $40000.0, down 21.57% from a year prior.
  • Depreciation & Amortization (CF) was $1000.0 for Q3 2025 at NovaBay Pharmaceuticals, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $32000.0 in Q4 2022 to a low of $1000.0 in Q2 2025.
  • A 5-year average of $14684.2 and a median of $13000.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): surged 233.33% in 2022, then plummeted 88.89% in 2025.
  • NovaBay Pharmaceuticals' Depreciation & Amortization (CF) stood at $26000.0 in 2021, then increased by 23.08% to $32000.0 in 2022, then tumbled by 62.5% to $12000.0 in 2023, then skyrocketed by 33.33% to $16000.0 in 2024, then crashed by 93.75% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Depreciation & Amortization (CF) are $1000.0 (Q3 2025), $1000.0 (Q2 2025), and $2000.0 (Q1 2025).